首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Codrituzumab ELISA Kit (KPTX234)

概述
图片
参考文献

概述

货号	KPTX234
品牌	ProteoGenix
描述	Codrituzumab ELISA Kit (KPTX234) — Quantitative colorimetric ELISA. for Codrituzumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Highlights High Sensitivity — Reliable quantification at low concentrations. Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型	Plasma, Serum
检测范围	0.31-5 μg/mL
保存溶液	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
检测方法	Colorimetric
实验类型	Quantitative
回收率	80-120%
运输	2-8 ℃
规格	Codrituzumab
别名	GC33, RG7686, RO5137382, CAS: 1365267-33-9
背景	Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer. The specific expression of GPC3 is high in hepatocellular carcinoma (HCC) tissues, which suggests that GPC3 has obvious sensitivity and specificity in the diagnosis of hepatocellular carcinoma, and can be used as a new target for the treatment of hepatocellular carcinoma. Codrituzumab did not show significant inhibition of GPC3 in the phase I trial in combined with sorafenib and the phase II trial placebo-controlled study in patients with advanced liver cancer. Codrituzumab did not show significant inhibition of GPC3 in phase I trials and phase II trials combined with sorafenib in patients with advanced liver cancer. However, the effect of codrituzumab in the treatment of liver cancer is still under study. In 2018, researchers conducted trials such as the distribution of codrituzumab and the impact of overall survival in patients with hepatocellular carcinoma. In the combined analysis of tumor cell surface antigen GPC3 and NK cell surface antigen CD16 in patients with liver cancer, it was found that codrituzumab only had a certain therapeutic effect on patients with high expression level of GPC3 and CD16. These results suggest that GPC3 and CD16 can be used as a composite biomarker to select hepatocellular carcinoma patients for codrituzuma.
Note	For Research Use Only.

图片

参考文献

公式

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

质量

=

浓度

×

体积

分子量 *

g/mol

公式

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

母液

C₁ (起始浓度)

×

V₁ (起始体积)

=

工作液

C₂ (终浓度)

×

V₂ (终体积)

相关产品推荐

Codrituzumab ELISA Kit

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有所有产品仅可用于工业或者科研等非医疗目的。

鄂ICP备2023002448号-2